Xenon Pharmaceuticals Inc
XENE
Get informed when a big investor buys or sells
+ FollowMarket Cap$5.44B
Close$
$2.34
96.6% downside
Current Fair Value
96.6% downsideOvervalued by 96.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $5.44 Billion |
|---|---|
| Enterprise Value | $4.90 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.36 |
| Beta | 0.61 |
| Outstanding Shares | 87,345,717 |
Return
| Return on Equity | -27.63% |
|---|---|
| Return on Assets | -27.63% |
| Return on Invested Capital | -30.26% |
Valuation & Multiples
| P/E Ratio | -14.66 |
|---|---|
| PEG | -25.6 |
| Price to Sales | - |
| Price to Book Ratio | 4.51 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -12.03 |
| Enterprise Value to Net Income | -13 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 11, 2026
EPS Estimate
$-1.17
Average shareholder expectationRevenue Estimate
$1.36 M
Average shareholder expectationNext Earnings Call
Expected Date
August 10, 2026
EPS Estimate
$-1.16
Average shareholder expectationRevenue Estimate
$1.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 115.56% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.06%▼ 126.40% |
|---|---|
| Total Invested | $3.02M▼ 99.95% |
| Investors Holding | 10▼ 296.00% |
ESG Score
No data
About Xenon Pharmaceuticals Inc
CEO: Simon Pimstone